Fig. 2From: Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPDPatient disposition figure. Patients were randomized into 1 of 120 treatment sequences. Each sequence included four out of the eight possible treatments administered for 14-day periods separated by 7- to 21-day washout periods. GP glycopyrrolate; MDI metered dose inhalerBack to article page